StromaCare was proud to take part in Future for Health, an event organized by the CCI FRANCE BELGIQUE, dedicated to fostering dialogue between innovators, pharma leaders, and investors shaping the future of healthcare. Our CEO, Georges Rawadi, presented how StromaCare is redefining disease treatment by targeting the stroma, a crucial yet often underestimated player in disease and tumor biology. Together with Karine Aguera , our team engaged in inspiring discussions about how we can collectively accelerate patient access to breakthrough therapies — advancing innovation for the benefit of both patients and the scientific community. #StromaCare #Innovation #HealthTech #Biotechnology #Oncology #FutureForHealth #CCIFB #LifeSciences
StromaCare
Biotechnology
Stromacare is a pioneer in tumoral stroma immuno-modulation and develops a therapeutic mAb for the treatment of cancers
About us
StromaCare is opening a new therapeutic avenue by targeting the tumoral Stroma, which is known to play a key role in several solid cancers, with the objective to be essential in the numerous anticancer protocols of treatment. Stromacare won the Beatrice Denys Foundation 2021 Prize (Foundation for Medical Research). The company is located in Lyon, France.
- Website
-
https://www.stroma.care
External link for StromaCare
- Industry
- Biotechnology
- Company size
- 2-10 employees
- Headquarters
- Lyon
- Type
- Privately Held
- Founded
- 2020
- Specialties
- oncology and monoclonal antibody
Locations
-
Primary
Get directions
28 rue Leannec
Lyon, 69008, FR
Employees at StromaCare
Updates
-
🎥 [INTERVIEW] : « Beaucoup de traitements contre le cancer échouent non pas par manque d’efficacité, mais parce qu’ils ne parviennent pas à atteindre leur cible à cause d’une barrière physique : le stroma » explique Georges Rawadi, CEO de StromaCare. 🎯 StromaCare développe une thérapie de rupture qui rend les tumeurs solides perméables aux traitements existants, en s’attaquant directement au stroma - cette barrière qui empêche les médicaments d’agir. Résultat : une amélioration de l’efficacité des traitements déjà disponibles et une augmentation du nombre de patients qui peuvent en bénéficier. 💪 🔬 Grâce au soutien de notre fonds Relyens Innovation Santé, Stromacare franchit des étapes déterminantes dans le chemin de développement vers la preuve de concept chez l’homme. « Nous avons l'ambition de porter cette innovation pour qu'elle puisse, demain, bénéficier à un grand nombre de patients atteints de cancers solides » ajoute Georges Rawadi. 🏆 Stromacare fait partie des 20 entreprises innovantes que nous accompagnons via notre fonds, conseillé par Turenne Santé. Notre ambition : faire émerger les innovations médicales les plus prometteuses, au service des professionnels de santé et de leurs patients. 📽️ Découvrez l’interview complète de Georges RAWADI dans notre série vidéo « Innov’action » ! Chez Relyens, nous soutenons des solutions de rupture en BioTech, MedTech et e-santé — au service de notre mission : « Agir et innover, aux côtés de celles et ceux qui œuvrent à l’intérêt général, pour construire un monde de confiance. » #InnovationSanté #Biotech #RelyensInnovationSanté #Stromacare Bervin BOUANI Benoît Pastour Sandrine Pernette Thomas Monnet
-
Exciting moments at Toulouse Oncoweek 2025! Thrilled to have our CEO, Georges Rawadi, presented StromaCare to share our vision for transforming pancreatic cancer treatment and how our innovative approach targets the tumor stroma to enhance therapeutic outcomes. Toulouse Oncoweek is an incredible gathering of experts, innovators, and leaders dedicated to advancing oncology research. Engaging with fellow scientists, clinicians, and industry peers reinforced the urgency and potential of our work. The fight against pancreatic cancer is complex, but collaboration and innovation will drive real impact. #Oncology #Biotech #Innovation #ToulouseOncoweek #PancreaticCancer #StromaCare
-
-
🎗️The fight against cancer is a global challenge, but new discoveries are giving us cause for hope🎗️ The tumor stroma, long considered a simple “support tissue” for the tumor, is now recognized as a key player in its progression and resistance to treatment. This complex microenvironment, made up of cells, blood vessels and extracellular matrix, can protect the tumor from attacks by the immune system and drugs. This is where our innovative approach comes in: immunomodulation of the tumor stroma. By targeting key players in the stroma, we aim to: --Make the tumor more vulnerable to immune cells and drugs. --Break the tumor's resistance to existing therapies. --Transform the stroma from an ally of the tumor into an asset for immunotherapy. Our work paves the way for new, more effective and better tolerated therapeutic strategies to improve the lives of cancer patients. 🥰 We are convinced that research into tumor stroma is a source of immense hope in the fight against cancer. 🥰 #Stromacare #worldcancerday #Cancer
-
StromaCare reposted this
🎀 𝐉𝐎𝐔𝐑𝐍𝐄𝐄 𝐌𝐎𝐍𝐃𝐈𝐀𝐋𝐄 𝐂𝐎𝐍𝐓𝐑𝐄 𝐋𝐄 𝐂𝐀𝐍𝐂𝐄𝐑 🎀 ▶️ 18 de nos participations interviennent de manière très concrète dans la lutte contre le cancer : 💊 en développant de nouveaux médicaments ou thérapies novatrices. 🩺 en soignant les patients. 🎗 en imaginant des technologies qui facilitent l'intervention des spécialistes. 👨🏻💻 en accélérant l'interprétation des données. 🧬 Autant d'apports qui bénéficient à l'avancée des connaissances dans le domaine du traitement de cette maladie qui aura touché 430 000 nouvelles personnes en France en 2023 (hommes à 57%, femmes à 43%). 📚 Retrouvez le 4e panorama des cancers en France qui regroupe toutes les données récentes sur la maladie (fréquence, taux de survie et de mortalité, âge médian du diagnostic...), publié par l'Institut national du cancer 👉 file:///C:/Users/drall/Downloads/Brochure_Panorama-2024_planches.pdf 🎞 Faites défiler notre carrousel pour en savoir plus sur les apports d'AlgoTx, Brenus Pharma, CellQuest, Centre Chirurgical des Princes, didactic - Dispositifs Médicaux, Elivie, Epigene Labs, ERBC GROUP, Exeliom Biosciences, Excellence Imagerie, GBNA Santé, HELPEVIA, Lifen, OREGA Biotech, Perha Pharmaceuticals, Quibim, StromaCare, SURGAR.
-
We are delighted to announce our participation and presentation at theToulouse Onco Week, February 5th to 7th, 2025. This event is the ideal opportunity to network with industry leaders, explore new collaborations and discover how our technologies can transform patient care. Join us to discover how our biotech solutions are transforming the medical landscape and bringing the hope of a cure a little closer for all.
-
-
World Pancreatic Cancer Day 🎗️ Today, at StromaCare, we stand in solidarity in the fight against pancreatic cancer, one of the most aggressive and challenging cancers to treat. Being the 3rd Leading cause of cancer death on average, research and innovation in targeted therapies have never been more essential to pancreatic cancer patients. At StromaCare, we are developing innovative treatments aimed at making the tumor microenvironment more accessible to immune cells and therapies by targeting key stromal proteins that contribute to tumor resistance. Our lead candidate, STRO-501, is designed to weaken this protective barrier around the cancer, enabling the immune system to act more effectively. On this World Pancreatic Cancer Day, we reaffirm our commitment to delivering new solutions for patients and their families, and to collaborating with the scientific community to improve outcomes for those affected by this disease. Together, let’s continue moving toward a future without pancreatic cancer. 💜 #WPCD #HelloPancreas #StromaCare #Innovation #CancerResearch #PancreaticCancer #Hope Ana Hennino Georges Rawadi Mélissa MASMOUDI Karine Aguera Sahar Kassem Sophie BACHY Sandrine Martins Coline Varigault Clémentine GEOFFROY
-